DNABW (Ginkgo Bioworks Holdings) Current Accrued Expense: $49.95 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNABW Ginkgo Bioworks Holdings Inc DNABW
62 GF Score
Price $0.00
! 5 Warning Signs
View Full Analysis

What is Ginkgo Bioworks Holdings Current Accrued Expense?

Ginkgo Bioworks Holdings DNABW 62 Current Accrued Expense is $49.95 Mil as of Jun. 2026. GuruFocus rates DNABW with a GF Score™ of 62/100. The stock has 5 warning signs investors should review.

Ginkgo Bioworks Holdings's Current Accrued Expense for the quarter that ended in Jun. 2026 was $49.95 Mil.

Ginkgo Bioworks Holdings's quarterly Current Accrued Expense increased from Dec. 2025 ($10.50 Mil) to Mar. 2026 ($48.38 Mil) and increased from Mar. 2026 ($48.38 Mil) to Jun. 2026 ($49.95 Mil).

Ginkgo Bioworks Holdings's annual Current Accrued Expense declined from Dec. 2023 ($34.19 Mil) to Dec. 2024 ($6.91 Mil) but then increased from Dec. 2024 ($6.91 Mil) to Dec. 2025 ($10.50 Mil).

Ginkgo Bioworks Holdings Current Accrued Expense Related Terms

Ginkgo Bioworks Holdings Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Ginkgo Bioworks Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ginkgo Bioworks Holdings Current Accrued Expense Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 52.27 32.86 34.19 6.91 10.50

Ginkgo Bioworks Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.23 79.34 10.50 48.38 49.95
DNABW
62GF Score
Ginkgo Bioworks Holdings Inc DNABW
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ginkgo Bioworks Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $49.95 Mil mean?
Ginkgo Bioworks Holdings (DNABW) has a Current Accrued Expense of $49.95 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Ginkgo Bioworks Holdings and its competitors.
Is Ginkgo Bioworks Holdings' Current Accrued Expense too high?
Ginkgo Bioworks Holdings' current Current Accrued Expense is $49.95 Mil. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Current Accrued Expense compare to RZLT and EIKN?
Ginkgo Bioworks Holdings' Current Accrued Expense of $49.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Ginkgo Bioworks Holdings and its competitors. Ginkgo Bioworks Holdings's current Current Accrued Expense is $49.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Ginkgo Bioworks Holdings (DNABW) has a current Current Accrued Expense of $49.95 Mil. The current Current Accrued Expense is $49.95 Mil. Ginkgo Bioworks Holdings' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNABW), the current Current Accrued Expense is $49.95 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ginkgo Bioworks Holdings Business Description

Other Exchanges DNA:USADNA:Mexico
Address 27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
62GF Score

Get the complete analysis for DNABW

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price